Publications

Export 108 results:
Author [ Title(Desc)] Type Year
Filters: Author is Serge Gauthier  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
C
Jia J, Gauthier S, Pallotta S, Ji Y, Wei W, Xiao S, Peng D, Guo Q, Wu L, Chen S et al..  2017.  Consensus-based recommendations for the management of rapid cognitive decline due to Alzheimer's disease.. Alzheimers Dement. 13(5):592-597.
Belleville S, LeBlanc AC, Kergoat M-J, Calon F, Gaudreau P, Hébert SS, Hudon C, Leclerc N, Mechawar N, Duchesne S et al..  2019.  The Consortium for the early identification of Alzheimer's disease-Quebec (CIMA-Q).. Alzheimers Dement (Amst). 11:787-796.
Wang H, Li T, Gauthier S, Yu E, Tang Y, Barbarino P, Yu X.  2020.  Coronavirus epidemic and geriatric mental healthcare in China: how a coordinated response by professional organizations helped older adults during an unprecedented crisis.. Int Psychogeriatr. :1-4.
Schoemaker D, Buss C, Head K, Sandman CA, Davis EP, Chakravarty MM, Gauthier S, Pruessner JC.  2018.  Corrigendum to "Hippocampus and amygdala volumes from magnetic resonance images in children: Assessing accuracy of FreeSurfer and FSL against manual segmentation"[NeuroImage 129 (2016) 1-14].. Neuroimage. 173:1-2.
D
Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H, Cedazo-Minguez A, Dubois B, Edvardsson D, Feldman H et al..  2016.  Defeating Alzheimer's disease and other dementias: a priority for European science and society.. Lancet Neurol. 15(5):455-532.
Wang H, Li T, Barbarino P, Gauthier S, Brodaty H, Molinuevo JLuis, Xie H, Sun Y, Yu E, Tang Y et al..  2020.  Dementia care during COVID-19.. Lancet. 395(10231):1190-1191.
Mortby ME, Black SE, Gauthier S, Miller D, Porsteinsson A, Smith EE, Ismail Z.  2018.  Dementia clinical trial implications of mild behavioral impairment.. Int Psychogeriatr. 30(2):171-175.
Gordon MForrest, Lenderking WR, Duhig A, Chandler J, J Lundy J, Miller DS, Piault-Louis E, Doody RS, Galasko D, Gauthier S et al..  2016.  Development of a patient-reported outcome instrument to assess complex activities of daily living and interpersonal functioning in persons with mild cognitive impairment: The qualitative research phase.. Alzheimers Dement. 12(1):75-84.
Zimmer ERigon, Leuzy A, Gauthier S, Rosa-Neto P.  2014.  Developments in Tau PET Imaging.. Can J Neurol Sci. 41(5):547-53.
Tourian L, Margolese HC, Gauthier S.  2014.  Donepezil-associated mania in two patients who were using donepezil without a prescription.. J Clin Psychopharmacol. 34(6):753-5.
E
Gauthier S, Rountree S, Finn B, LaPlante B, Weber E, Oltersdorf T.  2015.  Effects of the Acetylcholine Release Agent ST101 with Donepezil in Alzheimer's Disease: A Randomized Phase 2 Study.. J Alzheimers Dis. 48(2):473-81.
Florian H, Meier A, Gauthier S, Lipschitz S, Lin Y, Tang Q, Othman AA, Robieson WZ, Gault LM.  2016.  Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.. J Alzheimers Dis. 51(4):1237-47.
Gauthier S, Feldman HH, Schneider LS, Wilcock GK, Frisoni GB, Hardlund JH, Moebius HJ, Bentham P, Kook KA, Wischik DJ et al..  2016.  Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.. Lancet. 388(10062):2873-2884.
Gauthier S, Schlaefke S.  2014.  Efficacy and tolerability of Ginkgo biloba extract EGb 761® in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials.. Clin Interv Aging. 9:2065-77.
Benedet AL, Labbe A, Lemay P, Zimmer ER, Pascoal TA, Leuzy A, Mathotaarachchi S, Mohades S, Shin M, Dionne-Laporte A et al..  2015.  Epistasis analysis links immune cascades and cerebral amyloidosis.. J Neuroinflammation. 12:227.
Gauthier S, Rosa-Neto P, Kass JS.  2016.  Ethical Considerations for the Use of Next-Generation Alzheimer Drugs in Symptomatic and At-Risk Patients.. Continuum (Minneap Minn). 22(2 Dementia):615-8.
Vellas B., Sampaio C., Bateman R., Boxer A., Carrillo MC., Cummings J., Dubois B., Hampel H., Katz R., Khachaturian Z. et al..  2014.  E.U./U.S. CTAD Task Force on Alzheimer's Trial Populations. J Prev Alz Dis. 1:110-116.
F
Schoemaker D, Poirier J, D Collins L, Gauthier S, Pruessner JC.  2017.  Familiarity deficits in cognitively normal aging individuals with APOE ε4: A follow-up investigation of medial temporal lobe structural correlates.. Alzheimers Dement (Amst). 9:21-24.
Maria Rajah N, Wallace LMK, Ankudowich E, Yu EH, Swierkot A, Patel R, Chakravarty MM, Naumova D, Pruessner J, Joober R et al..  2017.  Family history and APOE4 risk for Alzheimer's disease impact the neural correlates of episodic memory by early midlife.. Neuroimage Clin. 14:760-774.
Therriault J, Pascoal TA, Benedet AL, Tissot C, Savard M, Chamoun M, Lussier F, Kang MSu, Berzgin G, Wang T et al..  2021.  Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, ε4, and Cognitive Impairment.. Neurology. 96(7):e975-e985.
Paquin V, Therriault J, Pascoal TAli, Rosa-Neto P, Gauthier S.  2020.  Frontal Variant of Alzheimer Disease Differentiated From Frontotemporal Dementia Using in Vivo Amyloid and Tau Imaging.. Cogn Behav Neurol. 33(4):288-293.
Ng KPin, Chiew HJin, Hameed S, Ting SKang Seng, Ng A, Soo SAnn, Wong BYX, Lim L, Yong ACW, Mok VCT et al..  2020.  Frontotemporal dementia and COVID-19: Hypothesis generation and roadmap for future research.. Alzheimers Dement (N Y). 6(1):e12085.
H
Wimo A, Ballard C, Brayne C, Gauthier S, Handels R, Jones RW, Jonsson L, Khachaturian AS, Kramberger M.  2014.  Health economic evaluation of treatments for Alzheimer's disease: impact of new diagnostic criteria.. J Intern Med. 275(3):304-16.
Schoemaker D, Buss C, Head K, Sandman CA, Davis EP, Chakravarty MM, Gauthier S, Pruessner JC.  2016.  Hippocampus and amygdala volumes from magnetic resonance images in children: Assessing accuracy of FreeSurfer and FSL against manual segmentation.. Neuroimage. 129:1-14.
Gauthier S, Leuzy A, Rosa-Neto P.  2014.  How can we improve transfer of outcomes from randomized clinical trials to clinical practice with disease-modifying drugs in Alzheimer's disease? Neurodegener Dis. 13(2-3):197-9.

Pages